Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
[en] ("[en] OBJECTIVES: To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs).
DESIGN: Prospective cohort study with 12 months of follow-up.
SETTING: Primary care in Belgium.
PARTICIPANTS: Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3648 eligible PHCPs from 2001 GP practices registered for this study (3044 and 604 to start in December 2020 and January 2021, respectively). 3390 PHCPs (92,9%) participated in their first testing time point (2820 and 565, respectively) and 2557 PHCPs (70,1%) in the last testing time point (December 2021).
INTERVENTIONS: Participants were asked to perform a rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points.
PRIMARY AND SECONDARY OUTCOME MEASURES: The prevalence, incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination.
RESULTS: Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI 13.5% to 16.6%), increased to 84.2% (95% CI 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) COVID-19 wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection.
CONCLUSIONS: This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation.
TRIAL REGISTRATION NUMBER: NCT04779424.","[en] ","")
Disciplines :
Public health, health care sciences & services
Author, co-author :
Adriaenssens, Niels ✱; Family Medicine & Population Health, Centre for General Practice, University of Antwerp Faculty of Medicine and Health Sciences, Antwerp (Wilrijk), Belgium
Scholtes, Béatrice ✱; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Bruyndonckx, Robin ; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Limburg, Belgium ; Epidemiology & Pharmacovigilance, P95, Leuven, Belgium ; Vaccine & Infectious Disease Institute, Laboratory of Medical Microbiology, University of Antwerp, Antwerp (Wilrijk), Belgium
Van Ngoc, Pauline ; Université de Liège - ULiège > Soins primaires et santé
Verbakel, Jan Yvan Jos ; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK ; Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium
De Sutter, An ; Department of Public Health and Primary Care, Ghent University, Gent, Belgium
Heytens, Stefan ; Department of Public Health and Primary Care, Ghent University, Gent, Belgium
Van Den Bruel, Ann ; Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium
Desombere, Isabelle ; Department of Infectious Diseases in Humans, Sciensano, Brussels, Belgium
Van Damme, Pierre ; Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp Faculty of Medicine and Health Sciences, Antwerp (Wilrijk), Belgium
Goossens, Herman ; Vaccine & Infectious Disease Institute, Laboratory of Medical Microbiology, University of Antwerp, Antwerp (Wilrijk), Belgium
Buret, Laetitia ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Duysburgh, Els ✱; Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium
Coenen, Samuel ✱; Family Medicine & Population Health, Centre for General Practice, University of Antwerp Faculty of Medicine and Health Sciences, Antwerp (Wilrijk), Belgium samuel.coenen@uantwerpen.be ; Vaccine & Infectious Disease Institute, Laboratory of Medical Microbiology, University of Antwerp, Antwerp (Wilrijk), Belgium
✱ These authors have contributed equally to this work.
Language :
English
Title :
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
WHO. WHO coronavirus (COVID-19) Dashboard. Available: https:// covid19.who.int [Accessed 9 Jun 2022].
Alter G, Seder R. The power of antibody-based surveillance. N Engl J Med 2020;383:1782-4.
Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through serological studies. Nat Med 2020;26:1171-2.
Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724-34.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535-44.
Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 2020;324:1781-2.
Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020;26:1200-4.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020;383:1085-7.
Yao L, Wang G-L, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis 2021;224:586-94.
Duysburgh E, Mortgat L, Barbezange C, et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis 2021;21:163-4.
Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med 2021;385:951-3.
Favresse J, Bayart J-L, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect 2021;10:1495-8.
Leclercq V, Van den Houte N, Gisle L, et al. Prevalence of Anti-SARS-CoV-2 antibodies and potential determinants among the Belgian adult population: baseline results of a prospective cohort study. Viruses 2022;14:920.
Merckx J, Vermeulen M, Vandermeulen C. Prevalence and incidence of antibodies against SARS-CoV-2 in children and school staff measured for one year in Belgium: a sero-epidemiological prospective cohort study. Available: https://www.sciensano.be/ nl/biblio/prevalence-and-incidence-antibodies-against-sars-cov-2-children-and-school-staff-measured-one-year [Accessed 9 Jun 2022].
Mortgat L, Verdonck K, Hutse V, et al. Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study. BMJ Open 2021;11:e050824.
De Sutter A, Heytens S, Duysburgh E. SARS-CoV-2 seroprevalence among nursing home staff and residents in Belgium: protocol. Available: https://www.sciensano.be/nl/biblio/sars-cov-2-seroprevalence-among-nursing-home-staff-and-residents-belgiumprotocol [Accessed 09 Jun 2022].
Pannus P, Neven K, De Craeye S. Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin Infect Dis 2021.
Adriaenssens N, Scholtes B, Bruyndonckx R, et al. Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol. BMJ Open 2022;12:e054688.
Starfield B. Is primary care essential? Lancet 1994;344:1129-33.
Starfield B. Primary care and health. JAMA 1991;266:2268-71.
Phadke I, McKee A, Conway JM, et al. Analysing how changes in the health status of healthcare workers affects epidemic outcomes. Epidemiol Infect 2021;149:E42.
Federale Overheidsdienst Volksgezondheid Veiligheid van de Voedselketen en Leefmilieu. Jaarstatistieken Met betrekking TOT de beoefenaars van gezondheidszorgberoepen in België, 2020. Available: https://overlegorganen.gezondheid.belgie.be/sites/default/ files/documents/statan_2019_-_nl.pdf [Accessed 17 May 2021].
Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri. Elenco dei Medici caduti nel corso dell'epidemia di Covid-19. Available: https://portale.fnomceo.it/elenco-dei-medicicaduti-nel-corso-dellepidemia-di-covid-19/ [Accessed 9 Jun 2022].
Mariën J, Ceulemans A, Bakokimi D, et al. Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium. Fam Pract 2022;39:92-8.
Triest D, Geebelen L, De Pauw R, et al. Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2. J Clin Virol 2021;142:104897.
LIANG K-YEE, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
Merckx J, Roelants M, Callies M. Prevalence and incidence of antibodies against SARS-CoV-2 in children and school staff measured between December 2020 and December 2021: Findings of the fifth testing period-brief summary. Available: https:// overlegorganen.gezondheid.belgie.be/sites/default/files/documents/ statan_2019_-_nl.pdf [Accessed 16 May 2022].
Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022;386:1207-20.
Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 2022;386:340-50.
Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults-United States, March-July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1156-62.
Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis 2022;22:967-76.
Cevik M, Grubaugh ND, Iwasaki A, et al. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 2021;184:5077-81.
Patel MK. Booster doses and prioritizing lives saved. N Engl J Med 2021;385:2476-7.
Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med 2021;385:2413-20.
Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med 2021;385:2421-30.
Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet 2022;399:715-7.
Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 2022;3:e52-61.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-11.
